Aa
hbsag loss by entecavir per genotype
http://www.ncbi.nlm.nih.gov/pubmed/25131947
J Med Virol. 2014 Aug 8. doi: 10.1002/jmv.24038. [Epub ahead of print]
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
Boglione L1, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
Author information
Abstract
The role of measurement of hepatitis B "s" antigen (HBsAg) during the therapy with oral nucleos(t)ide analogues is still debatable. The HBsAg declines after 3 years of therapy with entecavir (ETV) was investigated among patients affected by hepatitis B virus (HBV), e antigen (HBeAg)-negative and genotypes A, D and E. A prospective cohort of 123 patients was enrolled consecutively from April 2007 to May 2010 with at least 3 years of treatment with ETV. Patients with chronic HBV infection, HBeAg-negative, naive for previous treatment and with virological response to ETV were included in the study. HBsAg level and HBV-DNA were tested every 3 months during the first year of treatment, then every 6 months for a time of at least 3 years. After 3 years, HBsAg decline was 0.77 log IU/ml, 0.65 log IU/ml, 0.45 respectively; A versus D (P = 0.012), A versus E (P < 0.001), D versus E (P < 0.001). In the multivariate linear regression analysis only the HBV genotype was predictive of HBsAg decline after 3 years of treatment (P < 0.001). The expected time to HBsAg loss was 15.6 years for the A genotype, 17 years for D, 24.6 years for E (P < 0.001). The treatment with ETV leads the different kinetics in HBsAg decline among genotypes A, D and E; the expected time of HBsAg loss was significantly higher in E genotype compared to A and D genotype. J. Med. Virol. © 2014 Wiley Periodicals, Inc.
J Med Virol. 2014 Aug 8. doi: 10.1002/jmv.24038. [Epub ahead of print]
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
Boglione L1, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.
Author information
Abstract
The role of measurement of hepatitis B "s" antigen (HBsAg) during the therapy with oral nucleos(t)ide analogues is still debatable. The HBsAg declines after 3 years of therapy with entecavir (ETV) was investigated among patients affected by hepatitis B virus (HBV), e antigen (HBeAg)-negative and genotypes A, D and E. A prospective cohort of 123 patients was enrolled consecutively from April 2007 to May 2010 with at least 3 years of treatment with ETV. Patients with chronic HBV infection, HBeAg-negative, naive for previous treatment and with virological response to ETV were included in the study. HBsAg level and HBV-DNA were tested every 3 months during the first year of treatment, then every 6 months for a time of at least 3 years. After 3 years, HBsAg decline was 0.77 log IU/ml, 0.65 log IU/ml, 0.45 respectively; A versus D (P = 0.012), A versus E (P < 0.001), D versus E (P < 0.001). In the multivariate linear regression analysis only the HBV genotype was predictive of HBsAg decline after 3 years of treatment (P < 0.001). The expected time to HBsAg loss was 15.6 years for the A genotype, 17 years for D, 24.6 years for E (P < 0.001). The treatment with ETV leads the different kinetics in HBsAg decline among genotypes A, D and E; the expected time of HBsAg loss was significantly higher in E genotype compared to A and D genotype. J. Med. Virol. © 2014 Wiley Periodicals, Inc.
not really so important, there are only minor variations between architect and elecsys.it is important to use always the same machine so you exclude this variability while monitoring
the only dangerous mutations are made by lam and adv resistance (but may occur naturally too) where you also have hbsag and hbsab, these promotes hcc and cirrhosis even when hbvdna und, i think they are part in the occult hbv too
the only dangerous mutations are made by lam and adv resistance (but may occur naturally too) where you also have hbsag and hbsab, these promotes hcc and cirrhosis even when hbvdna und, i think they are part in the occult hbv too
But interferon can do all this in a year for.most people.
Do they measure toxicity with etv? I had lipodistrophy hit me on the year 7. Plus other sides that etv causes.
It does not justify to use nukes alone for this long. Combo treatment yes with immune modulator. But taking it as long as we did it is not a way to go.
And their own big pharma studies prove it. I guess sure is they would like to delay hbv cure for another decade.
Do they measure toxicity with etv? I had lipodistrophy hit me on the year 7. Plus other sides that etv causes.
It does not justify to use nukes alone for this long. Combo treatment yes with immune modulator. But taking it as long as we did it is not a way to go.
And their own big pharma studies prove it. I guess sure is they would like to delay hbv cure for another decade.
I've seen elsewhere they talks about HBSAG mutants which show low hbsag but high viral load. Do you know much about that?
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
